Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARRAY BIOPHARMA INCARRY · Entity 155788 | General Counsel | January 29, 2019 | February 07, 2019 |
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | September 23, 2024 | September 25, 2024 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Chief Legal Officer | February 02, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARRAY BIOPHARMA INC
Report date January 29, 2019 · Filed February 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,021 |
Ending reported balance
After 2019-02-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-01-29 · Exercise / conversion · Acquired 11,100 · Balance 15,021 Row 2 · 2019-02-05 · Exercise / conversion · Acquired 40,000 · Balance 55,021 Row 3 · 2019-02-05 · Sale · Disposed 40,000 · Balance 15,021 F1: These trades were made pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.94 · Expires 2027-08-15 | Direct | 363,900 |
Reported balance
After 2019-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-05 · Exercise / conversion · Disposed 40,000 · Balance 363,900 F2: The option vests in four equal annual installments beginning August 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These trades were made pursuant to a Rule 10b5-1 trading plan.
F2: The option vests in four equal annual installments beginning August 15, 2018.
AVENUE THERAPEUTICS, INC.
Report date September 23, 2024 · Filed September 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2034-09-23 | Direct | 30,000 |
Reported balance
After 2024-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-23 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.
Fulcrum Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2036-02-01 | Direct | 170,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 170,000 · Balance 170,000 F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 170,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001193125-26-037576 · ownership.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 3,452 | $12.92 | $44,599.84 |
DisclosureSEC source: 0001193125-25-322740 · ownership.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,252 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. F2 · balance_after: Includes 10,252 shares that were previously acquired under the Issuer's employee stock purchase plan. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-25-009813 · ownership.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2035-01-24 F1 · derivative.exercise_date: This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| September 23, 2024 Filed Sep 25, 2024 20:55 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001104659-24-102837 · tm2424771-5_4seq1.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 02:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0000950170-24-009092 · ownership.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-01-25 F1 · derivative.exercise_date: This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:07 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantEmployee stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001104659-23-078090 · tm2320488-2_4seq1.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-30 F1 · derivative.exercise_date: The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026. F2 · derivative.underlying_shares: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 127,500 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-23-015824 · ownership.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2033-04-25 F1 · derivative.exercise_date: These stock options were granted to the reporting person under the Fulcrum 2019 Stock Incentive Plan (the "Plan") as part of an executive retention program and will vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years, such that the options will be vested in full on the four-year anniversary of the grant date, and subject to the reporting person's continuing to be an "Eligible Participant" (as defined in the Plan) on each such vesting date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0000899243-23-004745 · doc4.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2023 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0000899243-22-028368 · doc4.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: This option was granted on August 9, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of August 9, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $12.69 | $0.00 |
DisclosureSEC source: 0000899243-22-002877 · doc4.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 21:24 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GrantCommon Stock | 49,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-152195 · tm2135922-5_4seq1.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,020 F1 · shares: This restricted stock award (RSA) vests on December 17, 2024, three years after the date granted. Read SEC document |
| December 17, 2021 Filed Jan 7, 2022 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GiftCommon Stock | 1,088 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001356 · doc5.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,248 F1 · balance_after: Consists of 1,248 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on November 12, 2021. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 1,088 | $9.01 | $9,802.88 |
DisclosureSEC source: 0000899243-21-026556 · doc4.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088 Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 153,600 | $0.00 Strike: $11.82 | $0.00 |
DisclosureSEC source: 0000899243-20-032867 · doc4.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,600 Underlying: Common Stock · 153,600 shares Expires 2030-12-02 F1 · derivative.exercise_date: This option was granted on December 3, 2020 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 30, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:30 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-19-000816 · primarydocument.xml · derivative · entry 4 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,900 Underlying: Common Stock · 40,000 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:30 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 40,000 | $20.00 | $800,000.00 |
DisclosureSEC source: 0001562180-19-000816 · primarydocument.xml · nonDerivative · entry 3 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,021 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:30 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 40,000 | $8.94 | $357,600.00 |
DisclosureSEC source: 0001562180-19-000816 · primarydocument.xml · nonDerivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2019 Filed Jan 29, 2019 16:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-19-000564 · primarydocument.xml · derivative · entry 4 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,900 Underlying: Common Stock · 11,100 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
| January 29, 2019 Filed Feb 7, 2019 16:30 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 11,100 | $8.94 | $99,234.00 |
DisclosureSEC source: 0001562180-19-000816 · primarydocument.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,029 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-19-000564 · primarydocument.xml · derivative · entry 3 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,000 Underlying: Common Stock · 14,029 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 14,029 | $18.00 | $252,523.40 |
DisclosureSEC source: 0001562180-19-000564 · primarydocument.xml · nonDerivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $18.00 to $18.001. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 16:27 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 14,029 | $8.94 | $125,419.26 |
DisclosureSEC source: 0001562180-19-000564 · primarydocument.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 16:47 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,251 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-19-000430 · primarydocument.xml · derivative · entry 3 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,029 Underlying: Common Stock · 1,251 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 16:47 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 1,251 | $18.00 | $22,518.00 |
DisclosureSEC source: 0001562180-19-000430 · primarydocument.xml · nonDerivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 16:47 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 1,251 | $8.94 | $11,183.94 |
DisclosureSEC source: 0001562180-19-000430 · primarydocument.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:58 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,720 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-19-000338 · primarydocument.xml · derivative · entry 3 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,280 Underlying: Common Stock · 19,720 shares Expires 2027-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:58 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 19,720 | $18.06 | $356,139.26 |
DisclosureSEC source: 0001562180-19-000338 · primarydocument.xml · nonDerivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported for these shares is the weighted average sale price of transactions made at prices from $18.00 to $18.17. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:58 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 19,720 | $8.94 | $176,296.80 |
DisclosureSEC source: 0001562180-19-000338 · primarydocument.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 7,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005028 · primarydocument.xml · derivative · entry 5 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 7,000 shares Expires 2021-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The RSUs vested and were settled in common stock on December 16, 2018. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Tax withholdingCommon Stock | 3,079 | $15.97 | $49,171.63 |
DisclosureSEC source: 0001562180-18-005028 · primarydocument.xml · nonDerivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921 F2 · shares: Represents shares withheld to satisfy tax withholding obligations of the reporting person. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005028 · primarydocument.xml · nonDerivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted on December 27, 2016 and December 16, 2017, as a result of the vesting of one fourth of such RSUs. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 116,250 | $0.00 Strike: $15.97 | $0.00 |
DisclosureSEC source: 0001562180-18-005028 · primarydocument.xml · derivative · entry 4 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,250 Underlying: Common Stock · 116,250 shares Expires 2028-12-16 F4 · derivative.exercise_date: The options vest in four equal annual installments beginning on December 16, 2019. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 19:48 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 19,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-005028 · primarydocument.xml · derivative · entry 3 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,375 Underlying: Common Stock · 19,375 shares Expires 2022-12-20 F3 · derivative.exercise_date: RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest and will be settled in common stock in four equal annual installments beginning on December 16, 2019. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:08 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 168,000 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0001562180-17-003959 · primarydocument.xml · derivative · entry 2 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2027-12-16 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on December 16, 2018. Read SEC document |
| December 16, 2017 Filed Dec 19, 2017 21:08 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 28,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003959 · primarydocument.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2021-12-17 F1 · derivative.exercise_date: Consists of RSUs awarded to the reporting person for no additional cash consideration each of which represent a contingent right to receive one share of Array BioPharma Inc. common stock. The RSUs vest and will be settled in stock in four equal annual installments beginning on December 16, 2018. Read SEC document |
| August 15, 2017 Filed Aug 17, 2018 17:19 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-18-003685 · primarydocument.xml · derivative · entry 1 Oltmans Curtis Gale · CIK 0001714982 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-08-15 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning August 15, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.